Cargando…
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y(12) receptor antagonist, in patients with chronic coronary syndromes
AIMS: To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y(12) receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). METHODS AND RESULTS: In this double-blind, randomized study of 345 patients with CCS on background oral anti...
Autores principales: | Storey, Robert F, Gurbel, Paul A, ten Berg, Jurrien, Bernaud, Corine, Dangas, George D, Frenoux, Jean-Marie, Gorog, Diana A, Hmissi, Abdel, Kunadian, Vijay, James, Stefan K, Tanguay, Jean-Francois, Tran, Henry, Trenk, Dietmar, Ufer, Mike, Van der Harst, Pim, Van't Hof, Arnoud W J, Angiolillo, Dominick J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556746/ https://www.ncbi.nlm.nih.gov/pubmed/31994703 http://dx.doi.org/10.1093/eurheartj/ehz807 |
Ejemplares similares
-
Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation
por: Curry, Benjamin J., et al.
Publicado: (2023) -
Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
por: Hsin, Chih-hsuan, et al.
Publicado: (2023) -
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022) -
Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020) -
The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
por: Crescence, Lydie, et al.
Publicado: (2021)